



Practitioner's Docket No. MP102-110P1RNM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Shomir Ghosh et al.

Application No.: 10/678,872

Group No.:

Filed: October 3, 2003

Examiner: N/A

For: PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF
INFLAMMATORY DISEASES

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. Preliminary Statement;
2. Forms PTO/SB/08A and 08B (substitute for Form PTO-1449);
3. Copies of listed Information items accompanying this Statement (AA-AM,BA-BT)

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

with sufficient postage as first class mail.


37 C.F.R. SECTION 1.10*

as "Express Mail Post Office to Address"
Mailing Label No.

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

Signature


Allan N. Kutzenco
(type or print name of person certifying)

Date: January 12, 2003

***WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.



Practitioner's Docket No. MPI02-110P1RNM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Shomir Ghosh et al.
Application No.: 10/678,872 Group No.:
Filed: October 3, 2003 Examiner: N/A
For: PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF
INFLAMMATORY DISEASES

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

1. The information disclosure statement submitted herewith is being filed:

Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

OR

After three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

(1) a final action under Section 1.113,

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail. as "Express Mail Post Office to Address" Mailing Label No. _____

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

Date: January 12, 2003

Signature


Allan N. Kutzenco
(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.



actioner's Docket No. MPI02-110P1RNM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Shomir Ghosh et al.
Application No.: 10/678,872 Group No.:
Filed: October 3, 2003 Examiner: N/A
For: PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF
INFLAMMATORY DISEASES

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL

1. Transmitted herewith for this application are:
 - a. This Transmittal;
 - b. Preliminary Amendment (3 pages);
 - c. Transmittal of Information Disclosure Statement (2 pages);
 - d. Information Disclosure Statement (2 pages);
 - e. Form PTO/SB/08A (1 page);
 - f. Form PTO/SB/08B (1 page);
 - g. References cited (AA-AM, BA-BT); and
 - h. Return postcard.

STATUS

2. Applicant is other than a small entity.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"
Mailing Label No.

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

Signature

Allan N. Kutzenco

(type or print name of person certifying)

Date: January 12, 2003

***WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.



Practitioner's Docket No. MPI02-110P1RNM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|-----------------------|--|------------|-----|
| In re application of: | Shomir Ghosh et al. | | |
| Application No.: | 10/678,872 | Group No.: | |
| Filed: | October 3, 2003 | Examiner: | N/A |
| For: | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | | |

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PRELIMINARY AMENDMENT

Dear Sir:

Prior to examination, please amend the application as follows:

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)


37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"
Mailing Label No. _____

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office. (703) 872-9300


Signature

Allan N. Kutzeneo

(type or print name of person certifying)

Date: January 12, 2003

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI02-110P1RNM

IN THE SPECIFICATION

On page 1, after the title, please insert:

CROSS-REFERENCE TO RELATED APPLICATION

This application claims the benefit of U.S. Provisional Application 60/416,501, filed October 4, 2002.

REMARKS


No new matter has been added by way of amendment, and Applicants submit that the application is now in condition for examination.

Respectfully submitted,

January 12, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By


Allan N. Kutzenco
Registration No. 38,945
40 Landsdowne Street
Cambridge, MA 02139
Telephone - (617) 444-1598
Facsimile - (617) 551-8820

Practitioner's Docket No. MPI02-110P1RNM

Preliminary Statement

Pursuant to 37 CFR 1.56, 1.97 and 1.98, applicants submit herewith patents, publications or other information, which may be material to the examination of this application.

No representation is made regarding whether the information cited herein is prior art to applicants' claimed invention or whether that information is material to patentability of the claims.


For the Examiner's convenience, applicants have listed several patents and patent applications that have published in the period between the filing of the priority document (S.N. 60/416501, filed October 4, 2002) and this application (filed October 3, 2003). For these documents, the letter designation "-p" has been added as suffix to the citation number (e.g., AK-p).

Copies of Listed Information Items Accompanying This Statement

Copies of all items listed in Forms PTO/SB/08A and 08B (substitute for Form PTO-1449) accompany this information disclosure statement.

January 12, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By: 
Allan N. Kutzenco
Attorney for Applicant
Reg. No. 38,945
40 Landsdowne Street
Cambridge, MA 02139
Telephone: (617) 444-1598
Facsimile - (617) 551-8820

Practitioner's Docket No. MPI02-110P1RNM

- (2) a notice of allowance under Section 1.311, or
- (3) an action that otherwise closes prosecution in the application

whichever occurs first.

[] Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c), (\$180.00).

Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

[] No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

FEE PAYMENT

2. The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).

Applicant believes no fee is due in connection with this submission.

Fee due \$0.00

METHOD OF PAYMENT OF FEE

3. Attached is a check in the amount of \$_____.
 Charge Account No. 501668 in the amount of \$0.00
 A duplicate of this request is attached.

If any additional fees are due, please charge Account 501668.


January 12, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By Allan N. Kutzenco
Allan N. Kutzenco
Attorney for Applicant
Reg. No. 38,945
40 Lansdowne Street
Cambridge, MA 02139
Telephone: (617) 444-1598
Facsimile - (617) 551-8820

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|------------------------|---------------|
| Substitute for form 1449A/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | | | |
| Sheet | 2 | of | 2 | Attorney Docket Number | «File_Ref_No» |



| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|-----------------------|------------------------|-------------------|---|--|---|
| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document (MM-DD-YYYY) | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Kind Code ² | Number (if known) | | | |
| | | | | | | |
| | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|-----------------------|-------------------------|--|---|--|---|-----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document (MM-DD-YYYY) | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | |
| | | Office ³ | Kind Code ⁵ Number ⁴ (if known) | | | | |
| | BL | WO | 02058652 (Abstract and structures only in English) | A1 | Henkel Kommanditgesellschaft Auf Aktien | 08-01-2002 | entire document |
| | BM | WO | 0211710 | A2 | Pfizer Products Inc. | 02-14-2002 | entire document |
| | BN | WO | 0218361 | A2 | Allergan Sales Inc. | 03-07-2002 | entire document |
| | BO-p | WO | 02079165 | A1 | Astrazeneca AB | 10-10-2002 | entire document |
| | BP-p | WO | 02088069 | A2 | Pfizer Products Inc. | 11-07-2002 | entire document |
| | BQ | WO | 0222585 | A1 | Kaken Pharm. Co., Ltd. | 03-21-2002 | entire document |
| | BR | WO | 03097042 (Abstract and structures only in English) | A1 | Shionogi & Co., Ltd. | 11-27-2003 | entire document |
| | BS | WO | 03097598 (Abstract and structures only in English) | A1 | Shionogi & Co., Ltd. | 11-27-2003 | entire document |
| | BT | JP | P200253557 (Structures only in English) | A | | 02-19-2002 | entire document |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| | | |
|--------------------|--|-----------------|
| Examiner Signature | | Date Considered |
|--------------------|--|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | | | |
|--|---|----|---|--|-----------------|--------------------------|--|
| Substitute for form 1449A/PTO | | | | JAN 14 2004 U.S. PATENT AND TRADEMARK OFFICE 955 | | <i>Complete if Known</i> | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | | | | | |
| Sheet | 1 | of | 1 | Application Number | 10/678872 | | |
| | | | | Filing Date | October 3, 2003 | | |
| | | | | First Named Inventor | Ghosh, Shomir | | |
| | | | | Group Art Unit | | | |
| | | | | Examiner Name | N/A | | |
| | | | | Attorney Docket Number | MPI02-110PIRNM | | |

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|-----------------------|----------------------|-----------------------------|---|--|---|
| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document (MM-DD-YYYY) | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Kind | Code ² Number | | | |
| AA | 6048873 | | | Vasudevan et al. | 04-11-2000 | entire document |
| AB | 6147089 | | | DeNinno et al. | 11-14-2000 | entire document |
| AC | 6197786 | B1 | | DeNinno et al. | 03-06-2001 | entire document |
| AD | 6291677 | B1 | | Vasudevan et al. | 09-18-2001 | entire document |
| AE | 6310075 | B1 | | DeNinno et al. | 10-30-2001 | entire document |
| AF | 6313107 | B1 | | Vasudevan et al. | 11-06-2001 | entire document |
| AG | 6313142 | B1 | | Damon et al. | 11-06-2001 | entire document |
| AH | 6362198 | B1 | | Goldstein et al. | 03-26-2002 | entire document |
| AI | 6362199 | B1 | | DiFabio | 03-26-2002 | entire document |
| AJ | 6395751 | B1 | | DeNinno et al. | 05-28-2002 | entire document |
| AK-p | 6489478 | B1 | | DeNinno et al. | 12-03-2002 | entire document |
| AL-p | 6586448 | B1 | | DeNinno et al. | 07-01-2003 | entire document |
| AM-p | 6600045 | B2 | | Damon et al. | 04-17-2003 | entire document |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|-----------------------|-------------------------|--|---|--|---|--------------------------------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document (MM-DD-YYYY) | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Kind | Code ⁵ Office ³ | Number ⁴ (if known) | | | |
| BA | EP | A1 | 0987251 | Pfizer Products Inc. | 03-22-2000 | entire document | |
| BB | EP | A1 | 0992496 | Pfizer Products Inc. | 04-12-2000 | entire document | |
| BC | EP | A1 | 1125929 | Pfizer Products Inc. | 08-22-2001 | entire document | |
| BD | EP | A1 | 1221439 | Kaken Pharm. Co. Ltd. | 07-10-2002 | entire document | |
| BE | WO | A1 | 0006153 | Smithkline Beecham Corp. | 02-10-2000 | entire document | |
| BF | WO | A1 | 0017165 | Pfizer Products Inc. | 03-30-2000 | entire document | |
| BG | WO | A1 | 0017166 | Pfizer Products Inc. | 03-30-2000 | entire document | |
| BH | WO | A1 | 0140190 | Pfizer Products Inc. | 06-07-2001 | entire document | |
| BI | WO | A1 | 0149675 | Pharmacia Corp. | 07-12-2001 | entire document | |
| BJ | WO | A2 | 0158875 | Grunenthal GmbH | 08-16-2001 | entire document | US 2003/0087926 (English equivalent) |
| BK | WO | A1 | 0176629 | Takeda Chemical Industries, Ltd. | 10-18-2001 | entire document | US 2003/0216398 (English equivalent) |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Practitioner's Docket No. MPI02-110P1RNM

FEE DEFICIENCY

6. If any additional fee is required, charge Account No. 501668.

7. Correspondence Address

Direct all future correspondence to:

Customer Number 30405


OR

Intellectual Property Department
MILLENNIUM PHARMACEUTICALS, INC.
40 Landsdowne Street
Cambridge, MA 02139

January 12, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By



Allan N. Kutzenco
Registration No. 38945
40 Landsdowne Street
Cambridge, MA 02139
Telephone - 617-444-1598
Facsimile - 617-551-8820